Clovis Oncology Inc. said the European Commission provided conditional authorization for its medicine Rubraca to treat women with a certain type of ovarian cancer.
The Boulder, Colo.-based biopharmaceutical company said Rubraca, which is also known as rucaparib, was approved as a treatment for BRCA mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer patients who had been treated at least twice with chemotherapy and were unable to tolerate it any further.
The approval is conditional upon certain post-marketing commitments.
Clovis President and CEO Patrick Mahaffy said the company can now also submit a marketing authorization to use Rubraca as a treatment to stop the recurrence of cancer, an indication it is already approved for in the U.S.
